Replimune Group (REPL) Rating Lowered to Sell at Zacks Investment Research

Replimune Group (NASDAQ:REPL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

Shares of NASDAQ:REPL traded up $0.64 on Tuesday, hitting $10.92. The company’s stock had a trading volume of 2,752 shares, compared to its average volume of 40,433. Replimune Group has a 12 month low of $8.88 and a 12 month high of $23.55.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.06). As a group, sell-side analysts predict that Replimune Group will post -1.21 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the company. Omega Fund Management LLC bought a new position in shares of Replimune Group in the third quarter worth $82,166,000. Bain Capital Life Sciences Investors LLC bought a new position in shares of Replimune Group in the third quarter worth $45,707,000. Redmile Group LLC bought a new position in shares of Replimune Group in the third quarter worth $35,307,000. Foresite Capital Management IV LLC bought a new position in shares of Replimune Group in the third quarter worth $19,797,000. Finally, Foresite Capital Management III LLC bought a new position in shares of Replimune Group in the third quarter worth $12,552,000. 55.75% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply